Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C32H38F2N2O5S2 |
| Molecular Weight | 632.781 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCN(C1CCN(CC[C@H](C2=CC=C(C=C2)S(C)(=O)=O)C3=CC(F)=CC(F)=C3)CC1)C(=O)CC4=CC=C(C=C4)S(C)(=O)=O
InChI
InChIKey=SCXSQUUTGCWHFU-WJOKGBTCSA-N
InChI=1S/C32H38F2N2O5S2/c1-4-36(32(37)19-23-5-9-29(10-6-23)42(2,38)39)28-13-16-35(17-14-28)18-15-31(25-20-26(33)22-27(34)21-25)24-7-11-30(12-8-24)43(3,40)41/h5-12,20-22,28,31H,4,13-19H2,1-3H3/t31-/m1/s1
| Molecular Formula | C32H38F2N2O5S2 |
| Molecular Weight | 632.781 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
AZD5672 was developed by AstraZeneca for the treatment of rheumatoid arthritis. It was found that the drug inhibits P-glycoprotein and is a CCR5 antagonist. Exists hypothesis that inhibition of CCR5 can bring benefits in the treatment of rheumatoid arthritis. In July 2009, Phase-II for Rheumatoid arthritis was discontinued.
Originator
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Differential expression of chemokine receptors on peripheral blood, synovial fluid, and synovial tissue monocytes/macrophages in rheumatoid arthritis. | 2001 May |
|
| Balancing hERG affinity and absorption in the discovery of AZD5672, an orally active CCR5 antagonist for the treatment of rheumatoid arthritis. | 2012 Feb 15 |
| Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 19:47:58 GMT 2023
by
admin
on
Fri Dec 15 19:47:58 GMT 2023
|
| Record UNII |
61XQN688TW
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
780750-65-4
Created by
admin on Fri Dec 15 19:47:58 GMT 2023 , Edited by admin on Fri Dec 15 19:47:58 GMT 2023
|
PRIMARY | |||
|
DB11804
Created by
admin on Fri Dec 15 19:47:58 GMT 2023 , Edited by admin on Fri Dec 15 19:47:58 GMT 2023
|
PRIMARY | |||
|
61XQN688TW
Created by
admin on Fri Dec 15 19:47:58 GMT 2023 , Edited by admin on Fri Dec 15 19:47:58 GMT 2023
|
PRIMARY | |||
|
CHEMBL1951914
Created by
admin on Fri Dec 15 19:47:58 GMT 2023 , Edited by admin on Fri Dec 15 19:47:58 GMT 2023
|
PRIMARY | |||
|
100000175721
Created by
admin on Fri Dec 15 19:47:58 GMT 2023 , Edited by admin on Fri Dec 15 19:47:58 GMT 2023
|
PRIMARY | |||
|
16007088
Created by
admin on Fri Dec 15 19:47:58 GMT 2023 , Edited by admin on Fri Dec 15 19:47:58 GMT 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
TARGET -> INHIBITOR |
Did not reported any cardiovascular risk, but it was failed because of unclear reasons in
a phase IIb study for rheumatoid arthritis.
Ki
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
|
